Combining therapies can improve survival for early-stage breast cancer patients
April 04, 2007
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.
Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.
The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.
They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.
"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."
In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."
Journal of the National Cancer Institute
Related Tamoxifen Current Events and Tamoxifen News ArticlesCommon breast cancer subtype may benefit from personalized treatment approach
The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment.Mechanical forces driving breast cancer lead to key molecular discovery
The stiffening of breast tissue in breast-cancer development points to a new way to distinguish a type of breast cancer with a poor prognosis from a related, but often less deadly type, UC San Francisco researchers have found in a new study.Dartmouth Cancer Researchers Issue State-of-the-State on Genetic-Based Testing and Treatment for Breast Cancer
Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer.Second-most common breast cancer subtype may benefit from personalized treatment approach
The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.Breast cancer drug fights fungal disease
Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients.New models of drug-resistant breast cancer point to better treatments
Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine in St. Louis. Drug cuts breast cancer cases by more than 50 percent in high risk women
Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study published in the Lancet* today.High cholesterol fuels the growth and spread of breast cancer
A byproduct of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, researchers at the Duke Cancer Institute report.Hormones impact stress, memories, and understanding social cues
Research released today demonstrates unexpected roles that sex hormones may play in the cognitive function of females, including memory and interpreting social cues.New Genetic Discovery Could Reduce the Guesswork in Drug Dosing
The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say.
More Tamoxifen Current Events and Tamoxifen News Articles
Tamoxifen and Breast Cancer (Yale Fastback Series)|
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)
A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.
Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)|
by Philipp Y. Maximov (Author), Russell E. McDaniel (Author), V. Craig Jordan (Author)
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...
Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)|
by Laura Bertolaso (Author)
Il tamoxifen è un farmaco ampiamente usato per il trattamento e la prevenzione del più frequente istotipo di tumore mammario, quello positivo per i recettori degli estrogeni. Nonostante i notevoli successi nella pratica clinica derivanti dall'impiego di tale farmaco, essi non riguardano ancora la totalità delle pazienti. Questo libro espone i promettenti seppur preliminari risultati di uno studio iniziato nel 2010 volto ad analizzare sperimentalmente i fattori molecolari e genetici a potenziale carattere predittivo nella determinazione della risposta terapeutica.
Tamoxifen: A guide for clinicians and patients|
by V. Craig Jordan (Editor), Nancy G. Brinker (Editor)
The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change|
by Christiane Northrup M.D. (Author)
Dr. Christiane Northrup’s #1 New York Times bestseller The Wisdom of Menopause has inspired more than a million women with a dramatically new vision of midlife—and will continue to do so for generations to come. As Dr. Northrup has championed, the “change” is not simply a collection of physical symptoms to be “fixed,” but a mind-body revolution that brings the greatest opportunity for growth since adolescence. The choices a woman makes now—from the quality of her relationships to the quality of her diet—have the power to secure vibrant health and well-being for the rest of her life.
Now completely revised, this groundbreaking classic draws on the current research and medical advances in women’s health, and includes
• a new section on sex after 50—and...
Tamoxifen: Beyond the Antiestrogen|
by John A. Kellen (Author)
Tamoxifen is a drug used as an antisteroidal substance. This work looks at the effects of the Tamoxifen beyond the scope of simple oestrogen antagonism. It examines the numerous "side effects" of the drug and looks at the complexity of its actions.
Tamoxifen: New Hope in the Fight Against Breast Cancer|
by John F. Kessler (Author), Greg A. Annussek (Author)
On the market in the United States since 1978, tamoxifen is the most widely prescribed anti-cancer drug in the world. Recently, this powerful cancer fighter has been found to prevent breast cancer, and its use as a breast cancer preventive has been approved by the FDA. For women at high risk of breast cancer, tamoxifen provides a new option for prevention of this disease. Now, in this comprehensive, accessible guide, a medical doctor provides answers to the critical questions every woman should ask before considering preventive therapy or cancer treatment with tamoxifen.Should I consider myself at high risk of breast cancer?
Do the risks of breast cancer outweight the risks of taking tamoxifen?
How does tamoxifen compare with other prevention therapies?
What are the side effects...
Tamoxifen Concepts and Cancer: New Paradigms (Cancer Etiology, Diagnosis and Treatments: Pharmacology - Research, Safety Testing and Regulation)|
by Ramon Andrade De Mello (Editor)
Tamoxifen & Breast Cancer|
by Michael W. & Valerie J. Wiebe DEGREGORIO (Author)
Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).: An article from: Family Practice News|
by Mitchel L. Zoler (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 2002. The length of the article is 629 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Title: Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).
Author: Mitchel L. Zoler
Publication: Family Practice News (Magazine/Journal)
Date: October 15, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 20 Page: 35(1)
Distributed by Thomson...